Cargando…
Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice
A recent type 1 diabetes (T1D) clinical trial of rituximab (a B cell-depleting anti-CD20 antibody) achieved some therapeutic benefit in preserving C-peptide for a period of approximately nine months in patients with recently diagnosed diabetes. Our previous data in the NOD mouse demonstrated that co...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566105/ https://www.ncbi.nlm.nih.gov/pubmed/23405091 http://dx.doi.org/10.1371/journal.pone.0054712 |
_version_ | 1782258530648064000 |
---|---|
author | Sarikonda, Ghanashyam Sachithanantham, Sowbarnika Manenkova, Yulia Kupfer, Tinalyn Posgai, Amanda Wasserfall, Clive Bernstein, Philip Straub, Laura Pagni, Philippe P. Schneider, Darius Calvo, Teresa Rodriguez Coulombe, Marilyne Herold, Kevan Gill, Ronald G. Atkinson, Mark Nepom, Gerald Ehlers, Mario Staeva, Teodora Garren, Hideki Steinman, Lawrence Chan, Andrew C. von Herrath, Matthias |
author_facet | Sarikonda, Ghanashyam Sachithanantham, Sowbarnika Manenkova, Yulia Kupfer, Tinalyn Posgai, Amanda Wasserfall, Clive Bernstein, Philip Straub, Laura Pagni, Philippe P. Schneider, Darius Calvo, Teresa Rodriguez Coulombe, Marilyne Herold, Kevan Gill, Ronald G. Atkinson, Mark Nepom, Gerald Ehlers, Mario Staeva, Teodora Garren, Hideki Steinman, Lawrence Chan, Andrew C. von Herrath, Matthias |
author_sort | Sarikonda, Ghanashyam |
collection | PubMed |
description | A recent type 1 diabetes (T1D) clinical trial of rituximab (a B cell-depleting anti-CD20 antibody) achieved some therapeutic benefit in preserving C-peptide for a period of approximately nine months in patients with recently diagnosed diabetes. Our previous data in the NOD mouse demonstrated that co-administration of antigen (insulin) with anti-CD3 antibody (a T cell-directed immunomodulator) offers better protection than either entity alone, indicating that novel combination therapies that include a T1D-related autoantigen are possible. To accelerate the identification and development of novel combination therapies that can be advanced into the clinic, we have evaluated the combination of a mouse anti-CD20 antibody with either oral insulin or a proinsulin-expressing DNA vaccine. Anti-CD20 alone, given once or on 4 consecutive days, produced transient B cell depletion but did not prevent or reverse T1D in the NOD mouse. Oral insulin alone (twice weekly for 6 weeks) was also ineffective, while proinsulin DNA (weekly for up to 12 weeks) showed a trend toward modest efficacy. Combination of anti-CD20 with oral insulin was ineffective in reversing diabetes in NOD mice whose glycemia was controlled with SC insulin pellets; these experiments were performed in three independent labs. Combination of anti-CD20 with proinsulin DNA was also ineffective in diabetes reversal, but did show modest efficacy in diabetes prevention (p = 0.04). In the prevention studies, anti-CD20 plus proinsulin resulted in modest increases in Tregs in pancreatic lymph nodes and elevated levels of proinsulin-specific CD4+ T-cells that produced IL-4. Thus, combination therapy with anti-CD20 and either oral insulin or proinsulin does not protect hyperglycemic NOD mice, but the combination with proinsulin offers limited efficacy in T1D prevention, potentially by augmentation of proinsulin-specific IL-4 production. |
format | Online Article Text |
id | pubmed-3566105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35661052013-02-12 Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice Sarikonda, Ghanashyam Sachithanantham, Sowbarnika Manenkova, Yulia Kupfer, Tinalyn Posgai, Amanda Wasserfall, Clive Bernstein, Philip Straub, Laura Pagni, Philippe P. Schneider, Darius Calvo, Teresa Rodriguez Coulombe, Marilyne Herold, Kevan Gill, Ronald G. Atkinson, Mark Nepom, Gerald Ehlers, Mario Staeva, Teodora Garren, Hideki Steinman, Lawrence Chan, Andrew C. von Herrath, Matthias PLoS One Research Article A recent type 1 diabetes (T1D) clinical trial of rituximab (a B cell-depleting anti-CD20 antibody) achieved some therapeutic benefit in preserving C-peptide for a period of approximately nine months in patients with recently diagnosed diabetes. Our previous data in the NOD mouse demonstrated that co-administration of antigen (insulin) with anti-CD3 antibody (a T cell-directed immunomodulator) offers better protection than either entity alone, indicating that novel combination therapies that include a T1D-related autoantigen are possible. To accelerate the identification and development of novel combination therapies that can be advanced into the clinic, we have evaluated the combination of a mouse anti-CD20 antibody with either oral insulin or a proinsulin-expressing DNA vaccine. Anti-CD20 alone, given once or on 4 consecutive days, produced transient B cell depletion but did not prevent or reverse T1D in the NOD mouse. Oral insulin alone (twice weekly for 6 weeks) was also ineffective, while proinsulin DNA (weekly for up to 12 weeks) showed a trend toward modest efficacy. Combination of anti-CD20 with oral insulin was ineffective in reversing diabetes in NOD mice whose glycemia was controlled with SC insulin pellets; these experiments were performed in three independent labs. Combination of anti-CD20 with proinsulin DNA was also ineffective in diabetes reversal, but did show modest efficacy in diabetes prevention (p = 0.04). In the prevention studies, anti-CD20 plus proinsulin resulted in modest increases in Tregs in pancreatic lymph nodes and elevated levels of proinsulin-specific CD4+ T-cells that produced IL-4. Thus, combination therapy with anti-CD20 and either oral insulin or proinsulin does not protect hyperglycemic NOD mice, but the combination with proinsulin offers limited efficacy in T1D prevention, potentially by augmentation of proinsulin-specific IL-4 production. Public Library of Science 2013-02-06 /pmc/articles/PMC3566105/ /pubmed/23405091 http://dx.doi.org/10.1371/journal.pone.0054712 Text en © 2013 Sarikonda et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Sarikonda, Ghanashyam Sachithanantham, Sowbarnika Manenkova, Yulia Kupfer, Tinalyn Posgai, Amanda Wasserfall, Clive Bernstein, Philip Straub, Laura Pagni, Philippe P. Schneider, Darius Calvo, Teresa Rodriguez Coulombe, Marilyne Herold, Kevan Gill, Ronald G. Atkinson, Mark Nepom, Gerald Ehlers, Mario Staeva, Teodora Garren, Hideki Steinman, Lawrence Chan, Andrew C. von Herrath, Matthias Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice |
title | Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice |
title_full | Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice |
title_fullStr | Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice |
title_full_unstemmed | Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice |
title_short | Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice |
title_sort | transient b-cell depletion with anti-cd20 in combination with proinsulin dna vaccine or oral insulin: immunologic effects and efficacy in nod mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566105/ https://www.ncbi.nlm.nih.gov/pubmed/23405091 http://dx.doi.org/10.1371/journal.pone.0054712 |
work_keys_str_mv | AT sarikondaghanashyam transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT sachithananthamsowbarnika transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT manenkovayulia transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT kupfertinalyn transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT posgaiamanda transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT wasserfallclive transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT bernsteinphilip transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT straublaura transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT pagniphilippep transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT schneiderdarius transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT calvoteresarodriguez transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT coulombemarilyne transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT heroldkevan transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT gillronaldg transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT atkinsonmark transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT nepomgerald transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT ehlersmario transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT staevateodora transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT garrenhideki transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT steinmanlawrence transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT chanandrewc transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice AT vonherrathmatthias transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice |